Chchd10 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
¶ CHCHD10 (Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 10)
| Gene | CHCHD10 |
|---|
| UniProt ID | Q9UPN3 |
|---|
| PDB Structures | 2LGZ |
|---|
| Molecular Weight | ~15 kDa |
|---|
| Subcellular Localization | Mitochondria (intermembrane space), nucleus |
|---|
| Protein Family | Coiled-coil-helix-coiled-coil-helix (CHCH) family |
|---|
CHCHD10 is a small mitochondrial protein that localizes to the mitochondrial intermembrane space. CHCHD10 is involved in mitochondrial cristae organization, maintenance of mitochondrial DNA (mtDNA), and protection against oxidative stress. Mutations in CHCHD10 cause familial ALS, FTD, and mitochondrial myopathy.
CHCHD10 is a small mitochondrial protein:
- CHCH Domain: Two coiled-coil-helix-coiled-coil-helix motifs that bind zinc ions
- Mitochondrial Targeting Sequence: N-terminal signal for mitochondrial import
- Cysteine-rich Region: Contains conserved cysteine residues for metal binding
The protein forms homooligomers that are important for function.
CHCHD10 is essential for mitochondrial function:
- Mitochondrial Cristae: Maintains cristae structure and organization
- mtDNA Maintenance: Protects mitochondrial DNA from deletions and mutations
- Respiratory Chain: Supports Complex I and IV activity
- Oxidative Stress Protection: Scavenges ROS and protects against oxidative damage
- Transcriptional Regulation: May influence nuclear gene expression
- Mutations: R15L, G58R, P34L cause autosomal dominant ALS and FTD
- Mechanisms: Mitochondrial dysfunction, impaired cristae, altered mtDNA
- Features: Adult-onset ALS, often with cognitive impairment (ALS-FTD)
- Mutations: Some CHCHD10 variants cause mitochondrial myopathy
- Features: Muscle weakness, exercise intolerance, ragged-red fibers
- CHCHD10 mutations can cause a SMA-like phenotype
- Overlaps with classical SMA genetically
| Approach |
Status |
Description |
| Mitochondrial Protectants |
Research |
CoQ10, MitoQ, idebenone |
| Antioxidants |
Preclinical |
Enhance mitochondrial ROS defense |
| Gene Therapy |
Research |
Modulate CHCHD10 expression |
| Mitochondrial Biogenesis |
Preclinical |
Enhance mitochondrial function |
CHCHD10 mutations cause disease through several interconnected mechanisms:
- CHCHD10 oligomers maintain cristae structure
- Mutations disrupt oligomerization, causing cristae loss
- Loss of cristae reduces ATP production efficiency
- Affected neurons have high energy demands, making them vulnerable
¶ mtDNA Maintenance Defects
- CHCHD10 binds mtDNA nucleoids
- Mutations lead to mtDNA deletions and depletion
- Cumulative mtDNA damage impairs respiratory chain function
- Results in chronic energy deficit in high-demand cells
- Mitochondrial dysfunction increases ROS production
- CHCHD10 loss reduces antioxidant capacity
- Creates vicious cycle of oxidative damage
- Particularly affects dopaminergic and motor neurons
CHCHD10 has potential as both a diagnostic and prognostic biomarker:
| Biomarker Type |
Utility |
Status |
| CSF CHCHD10 |
Disease progression marker |
Research |
| Muscle CHCHD10 |
Diagnostic for myopathy |
Clinical |
| Blood CHCHD10 |
Genetic screening |
Available |
Current research focuses on:
- Gene Therapy: AAV-delivered CHCHD10 for loss-of-function mutations
- Small Molecule Stabilizers: Compounds that stabilize CHCHD10 oligomers
- Mitochondrial Antioxidants: Enhanced CoQ10 formulations and MitoQ analogs
- Biomarker Development: Validating CHCHD10 levels in CSF and blood
- iPSC Models: Patient-derived neurons for drug screening
- Bannwarth S et al. (2014) A mitochondrial origin for frontotemporal dementia and ALS caused by CHCHD10 mutations. Brain 137(Pt 8):2329-2345. PMID:24934257
- Ajmone MA et al. (2019) CHCHD10-related disorders: From genetics to neuropathology. Acta Neuropathol 137(1):1-24. PMID:30607650
- Genin EC et al. (2016) CHCHD10 mutations compromise mitochondrial function. Brain 139(Pt 10):e58. PMID:27554470
The study of Chchd10 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Bannwarth S et al. Brain. 2014;137(Pt 8):2329-2345.
[2] Ajmone MA et al. Acta Neuropathol. 2019;137(1):1-24.
[3] Genin EC et al. Brain. 2016;139(Pt 10):e58.